Please login to the form below

Not currently logged in
Email:
Password:

New US head for Daiichi Sankyo

Glenn Gormley replaces John Gargiulo who steps down as president and CEO

Daiichi Sankyo Glenn Gormley Daiichi Sankyo has announced a shake-up of its senior leadership team in the US.

John Gargiulo well step down as president and CEO of the group's US subsidiary Daiichi Sankyo Inc to be replaced by Dr Glenn Gormley, who takes on the role of president and chairman.

Dr Gormley (pictured right) will also continue in his existing roles as president, Daiichi Sankyo pharma development; global head of R&D; and senior executive officer.

In addition to the announcement that Gargiulo is to step down as president and CEO, he will also leave his role as head of Daiichi's commercial division. He is succeeded there by Greg Barrett, who now holds the title of acting president, Daiichi Sankyo administrative and commercial operations.

The move is a step up for Barrett, who most recently held the position of VP, marketing and managed markets in the US.

No reason was given for the departure of Gargiulo who has been with the company in the US since 1996.

8th October 2013

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics